Perform precision analysis of patient data and sample status with instant results. Turn the rapid growth of omics data to your advantage within the context of clinical trial, preclinical and public research data.
With IDBS you can improve data management and integration from many resources, streamline data capture and reporting, and enhance phenotypic and genotypic annotations – all in a secured audited environment. Advanced features, outstanding experience IDBS has 25 years’ experience working with large pharmaceutical and biotech companies, academic universities and research institutes, medical centers, and diagnostic labs. Patient Drug Response Modeling - Entelos.com.
Predict Likely Outcomes in Sub-populations For Scientists who need to address patient variability, Entelos models simulate diverse patient phenotypes and mechanisms to quantify and predict outcomes in specific sub-populations.
Biosimulation uses clinical data to test hypotheses in sub-populations to better stratify them with respect to efficacy and safety. Questions Biosimulation Can Answer Which biomarkers identify responders and non-responders? MediSapiens Ltd. Better Data. Better Decisions. Better Outcomes. Patient Stratification. Patient Stratification. Patient stratification involves the use of biomarkers to create subsets within a patient population that provide more detailed information about how the patient will respond to a given drug (gene responders).
Stratification can be a critical component in transforming a clinical trial from a negative or neutral outcome to one with a positive outcome by identifying the subset of the population most likely to respond to a therapy. GenetRx™ can be used to stratify patients using biomarkers (gene responders/non responders) to enrich a clinical trials population with one or more goals in mind including: Increasing the responder population Reducing the size, time & cost of a trial Improving overall results of your clinical trial The use of even moderately effective biomarkers, e.g. 70% sensitivity and specificity, can dramatically improve trial outcome.
For more information relating to our capabilities in providing information to patient stratification programs, please click here. Patient Stratification. Patient stratification involves the use of biomarkers to create subsets within a patient population.
Patient stratification involves the use of biomarkers to create subsets within a patient population that provide more detailed information about how the patient will respond to a given drug. Stratification can be a critical component to transforming a clinical trial from a negative or neutral outcome to one with a positive outcome by identifying the subset of the population most likely to respond to a novel therapy. Quinten. ARIANA Pharma. SeqWright - DNA Sequencing, Molecular Biology, and Custom Genomic Analysis Services.